Due to a production error, an incorrect Funding statement was used.
The correct Funding statement is “This study was funded by the National Key R&D Program of China (NO. 2019YFC1712000); Subject: Development of international standards for services in clinical pharmaceutical affairs of Chinese Patent Medicine and dispensing education (NO. 2019YFC1712002).”
The publisher apologizes for the mistake. The original version of this article has been updated.
Summary
Keywords
Chinese patent medicine, COVID-19, application regularity, correlative factor, retrospective analysis
Citation
Frontiers Production Office (2021) Erratum: A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China. Front. Pharmacol. 12:654045. doi: 10.3389/fphar.2021.654045
Received
15 January 2021
Accepted
15 January 2021
Published
25 February 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2021
Updates
Copyright
© 2021 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.